stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Book value per share
IDEAYA Biosciences, Inc.'s book value per share at the end of fiscal 2025 was 11.6×, down 10.8% from 13.0× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 10.6×. Over the past ten years it has ranged from −51.2× (fiscal 2018) to 13.0× (fiscal 2024); the current reading is higher than 89% of that period. IDEAYA Biosciences, Inc. ranks 76th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 11.6× | (10.85%) |
| FY2024 | 13.0× | 20.09% |
| FY2023 | 10.8× | 28.06% |
| FY2022 | 8.4× | (1.42%) |
| FY2021 | 8.6× | 6.65% |
| FY2020 | 8.0× | (0.17%) |
| FY2019 | 8.0× | — |
| FY2018 | −51.2× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 10.6× | (18.54%) |
| Jun 2026 | 13.0× | 23.24% |
| Mar 2026 | 10.6× | (8.60%) |
| Dec 2025 | 11.6× | (6.28%) |
| 31 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 13.5× |
| IDYA IDEAYA Biosciences, Inc. | 10.6× |
| BEAM Beam Therapeutics Inc. compare | 9.1× |
| DNLI Denali Therapeutics Inc. compare | 4.9× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.2× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| TLX Telix Pharmaceuticals Limited compare | 0.0× |
| CELC Celcuity, Inc. compare | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement